We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
GVK BIO Partners with Endo Pharmaceuticals
News

GVK BIO Partners with Endo Pharmaceuticals

GVK BIO Partners with Endo Pharmaceuticals
News

GVK BIO Partners with Endo Pharmaceuticals

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "GVK BIO Partners with Endo Pharmaceuticals"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Under this agreement GVK BIO will use its discovery expertise to deliver a clinical candidate and Endo will develop and commercialize the product arising out of this collaboration. This collaboration arose out of a newly launched concept at GVK BIO named Early Discovery Assets (EDA™).

Manni Kantipudi, CEO of GVK BIO commented, “We are delighted to partner with Endo as it continues to build its discovery pipeline through external collaborations. This collaboration also confirms the value of our differentiated EDATM concept, conceived to collaborate with pharmaceutical partners on discovery projects, from target to clinical candidates.”

Dr. Sandeep Gupta, Endo’s Senior Vice President of Drug Discovery and Early Development stated “We are pleased to initiate this discovery collaboration with GVK BIO. With their world class infrastructure and an experienced scientific team, I have no doubt that they will execute on the program goals and add to our portfolio of development candidates that provide novel treatment options for the patients”.

Advertisement